Showing 5631-5640 of 6964 results for "".
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres
- Dermatologists Issue Guidelines for Opioid Management Following 87 Common Procedureshttps://practicaldermatology.com/news/dermatologists-issue-guidelines-for-opioid-management-following-87-common-procedures/2460219/New dermatologic procedure-recommendations for opioid management seek to help curtail the opioid epidemic and reduce the number of opioid overdose deaths. The new consensus statement was developed by a group of 40 board-certified dermatologists, including Mohs micrographic surgeons, der
- Dr. Roy Geronemus Awarded the Inaugural Vic Narurkar, MD Innovations in Aesthetic Dermatology Lectureship Awardhttps://practicaldermatology.com/news/dr-roy-geronemus-awarded-the-vic-narurkar-md-innovations-in-aesthetic-dermatology-lectureship-award/2460210/Roy Geronemus, MD of Laser & Skin Surgery Center of New York received, The American Society for Dermatologic Surgery inaugural Vic Narurkar, M.D., Innovations in Aesthetic Dermatology Lectureship Award Dr. Geronemus received the award at the 2019 ASDS annual meeting in Chicago. He d
- FDA Accepts NDA for Cassiopea's Clascoterone Cream 1% for Acnehttps://practicaldermatology.com/news/fda-accepts-nda-for-cassiopeas-clascoterone-cream-1-for-acne-1/2460209/The FDA has accepted Cassiopea SpA's New Drug Application (NDA) for clascoterone cream 1% for review. Cassiopea, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological con
- It's Official: Venus Concept Completes Merger with Restoration Roboticshttps://practicaldermatology.com/news/its-official-venus-concept-completes-merger-with-restoration-robotics/2460207/Venus Concept Inc. has completed its previously announced merger with Restoration Robotic, Inc., effective November 7, 2019. Following the completion of the merger, Venus Concept completed a $28 million equity financing by EW Healthcare Partners, HealthQuest Capital, SEDCO Capital
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50
- Pinnacle Dermatology Acquires SkinSpeaks Dermatology Clinics in Twin Citieshttps://practicaldermatology.com/news/pinnacle-dermatology-acquires-skinspeaks-dermatology-clinics-in-twin-cities/2460205/Pinnacle Dermatology has acquired SkinSpeaks in the Twin Cities area including locations in Edina, Woodbury, Burnsville, Blaine and Crystal. “We welcome the patients and staff of SkinSpeaks to the Pinnacle Dermatology network of prac
- New AAD/NPF Guidelines Address Care for Pediatric Psoriasishttps://practicaldermatology.com/news/new-aadnpf-guidelines-address-care-for-pediatric-psoriasis/2460204/New guidelines from the American Academy of Dermatology and the National Psoriasis Foundation offer counsel on how to best manage psoriasis and its extracutaneous manifestations in children and adolescents. The
- Cynosure Enters the Muscle Toning Market in Europe, Middle Easthttps://practicaldermatology.com/news/cynosure-enters-the-muscle-toning-market-in-europe-middle-east/2460200/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,